Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
[89Zr]-Zr-DFO-simtuzumab (The Univ. of Chicago)
- Development stage
- Unknown
- Lead developer
- University of Chicago
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Positron Emitters → Radiopharmaceuticals, Gamma Emitters → Radiopharmaceuticals
01
Overview
[89Zr]-Zr-DFO-simtuzumab (The Univ. of Chicago): sourced facts only. name: "Magnetic bead-based assay confirmed specific binding of [89Zr]-Zr-DFO-simtuzumab to LOXL2." [PMID:42871741]; target: "Magnetic bead-based assay confirmed specific binding of [89Zr]-Zr-DFO-simtuzumab to LOXL2." [PMID:42871741]; developer: "Department of Radiology, The University of Chicago, Chicago, Illinois 63607, United States." [PMID:42871741]; modality: "Overall, simtuzumab has been successfully labeled with [89Zr]Zr using DFO and characterized as a candidate immunoPET tracer for LOXL2." [PMID:42871741]; stage: "microPET/CT imaging studies in mice bearing MIA PaCa-2 xenografts demonstrated low but visible uptake of [89Zr]-Zr-DFO-simtuzumab in tumors (6.2 ± 1.3% ID/g) at 96 h postinjection." [PMID:42871741]
02
Targets
LOXL2 (Lysyl oxidase-like 2 protein)
Beyond the preview
Go deeper on [89Zr]-Zr-DFO-simtuzumab (The Univ. of Chicago).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on [89Zr]-Zr-DFO-simtuzumab (The Univ. of Chicago).